Particle Therapy 2017
How important is mid-to-low dose? Reduction of secondary tumour risk
1.
Chung et al. IJROBP. 2013 Sep 1;87(1):46-52.)
Made with FlippingBook flipbook maker
How important is mid-to-low dose? Reduction of secondary tumour risk
1.
Chung et al. IJROBP. 2013 Sep 1;87(1):46-52.)
Made with FlippingBook flipbook maker